ACADIA Pharmaceuticals (ACAD)
(Delayed Data from NSDQ)
$16.74 USD
-0.36 (-2.11%)
Updated Apr 23, 2024 04:00 PM ET
After-Market: $16.74 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth F Momentum B VGM
Acadia Pharmaceuticals (ACAD) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$29.43 | $39.00 | $13.00 | 73.22% |
Price Target
Based on short-term price targets offered by 19 analysts, the average price target for Acadia Pharmaceuticals comes to $29.43. The forecasts range from a low of $13.00 to a high of $39.00. The average price target represents an increase of 73.22% from the last closing price of $16.99.
Analyst Price Targets (19)
Broker Rating
Acadia Pharmaceuticals currently has an average brokerage recommendation (ABR) of 1.80 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 20 brokerage firms. The current ABR compares to an ABR of 1.86 a month ago based on 21 recommendations.
Of the 20 recommendations deriving the current ABR, 12 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 60% and 10% of all recommendations. A month ago, Strong Buy made up 57.14%, while Buy represented 9.52%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 12 | 12 | 12 | 13 | 13 |
Buy | 2 | 2 | 2 | 2 | 2 |
Hold | 5 | 5 | 6 | 5 | 5 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 1 | 1 | 1 | 1 | 1 |
ABR | 1.80 | 1.80 | 1.86 | 1.76 | 1.76 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/12/2024 | Robert W. Baird & Co. | Joel L Beatty | Strong Buy | Strong Buy |
3/12/2024 | Mizuho SecuritiesUSA | Uy D Ear | Strong Buy | Hold |
3/12/2024 | Canaccord Genuity | Sumant Kulkarni | Strong Buy | Strong Buy |
3/12/2024 | Cantor Fitzgerald & Co | Charles C Duncan | Strong Buy | Strong Buy |
3/12/2024 | H.C. Wainwright & Co. | Andrew S Fein | Strong Buy | Strong Buy |
3/12/2024 | JMP Securities | Jason N Butler | Strong Buy | Strong Buy |
3/12/2024 | Needham & Company | Ami Fadia | Moderate Buy | Moderate Buy |
2/27/2024 | Guggenheim Securities | Yatin Suneja | Strong Buy | Strong Buy |
1/25/2024 | SVB Securities | Marc Goodman | Strong Buy | Strong Buy |
11/2/2023 | Not Identified | Not Identified | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.80 |
ABR (Last week) | 1.80 |
# of Recs in ABR | 20 |
Average Target Price | $29.43 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 77 of 252 |
Current Quarter EPS Est: | 0.18 |